IP Library › Granted Patent US 7,176,020
Granted Patent B2
US 7,176,020 · App. 10/320,608 · Granted Feb 13, 2007

EBV-infected stomach cancer cell line

Assignee: Eisai Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,176,020
App. No.
10/320,608
Granted
Feb 13, 2007
Kind
B2
Abstract

An EBV strain infecting epithelial cells and a stomach cancer cell line cancerated by EBV are established to clarify the mechanism of canceration of epithelial cells into stomach cancer by EBV and to develop a chemotherapeutic agent for stomach cancer cancerated by EBV. Further, a stomach cancer cell line stably producing EBV-related antigens is established to develop a diagnostic drug for stomach cancer cancerated by EBV. According to the present invention, GTC-4 cell line was established through culture of stomach cancer tissues. GTC-4 produced the EBV strain infecting epithelial cells and simultaneously produced EBV-related antigens stably in the supernatant.

Claims (4)

1. A method of screening a potential anticancer agent which comprises,

culturing GTC-4 (Budapest Treaty Deposit Accession No. 99012705) cells in the presence of a potential anticancer agent and

determining the effects of the potential anticancer agent on growth of the GTC-4 cells,

wherein an inhibition in growth of the GTC-4 cells is due to the activity of the anticancer agent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2007
From: EISAI CO., LTD.
To: EISAI R&D MANAGEMENT CO., LTD.
Reel/Frame 019500/0673 →
Priority Claims (1)
JP 11-27531 · Feb 4, 1999 · national
Continuity (3)
Division 0988203400 · Jun 18, 2001
Division 0938546700 · Aug 30, 1999
Related Publication 20030092084A1 · May 15, 2003